Corporate News – Mira Pharmaceuticals, Inc. (MIRA)

Mira Pharmaceuticals, Inc. (NASDAQ: MIRA) concluded a trading session on Friday, 23 October 2026 with its shares rising 4.92 % to USD 0.61 at 07:18 PM Central Europe. The stock, which has a market capitalization of USD 28.7 million and a circulating supply of 42 million shares, generated approximately USD 87.8 k in volume during the last 24 hours. The 200‑day simple moving average currently sits at USD 1.00, underscoring a prolonged downtrend, while the 52‑week high (USD 1.80 on 28 October 2025) and 52‑week low (USD 0.60 on 3 August 2026) frame the recent price volatility.

Recent Clinical Milestone

On 22 October 2026, Mira announced the results of a 21‑day pre‑clinical study of its lead candidate MIRA‑55, an oral synthetic cannabinoid analogue designed to address chronic inflammatory pain. Key findings include:

  • Significant attenuation of both mechanical and thermal pain thresholds, matching the analgesic efficacy of the NSAID celecoxib.
  • No observable tolerance over the study period, with pain relief sustained throughout.
  • Reduced inflammation‑associated swelling, indicating a dual anti‑pain and anti‑inflammatory profile.
  • Consistent efficacy across male and female cohorts, with no adverse clinical signs reported.

These outcomes reinforce the decision to pursue an IND‑enabling development program. Mira intends to file an Investigational New Drug application in the first quarter of 2027, aligning with its strategy to advance MIRA‑55 alongside other pain‑focused candidates.

Market Context

The broader market environment reflects a mix of modest gains and declines:

  • Pixelworks (PXLW) fell 4.66 % to USD 5.36, with a market cap of USD 33.8 million.
  • Koss (KOSS) edged up 0.29 % to USD 3.52, market cap USD 32.9 million.
  • Xbp Global (XBP) dropped 2.56 % to USD 2.94, market cap USD 33.9 million; P/E ratio 0.03.
  • Celularity (CELU) slid 19.05 % to USD 0.97, market cap USD 33.1 million; recently restored Nasdaq compliance and is refining its finance and reporting practices.
  • Qt Imaging (QTI) declined 0.86 % to USD 2.34, market cap USD 33.8 million.

Mira’s performance stands in contrast to the broader cohort, suggesting resilience amid a generally cautious market sentiment.

Strategic Implications

Mira’s focus on CB1/CB2‑targeted therapeutics positions it uniquely within the chronic pain arena, offering a potentially safer alternative to marijuana‑derived products. The successful pre‑clinical data for MIRA‑55 not only validates the company’s platform but also strengthens its pipeline narrative, potentially attracting further capital and partnership opportunities.

Given the company’s global customer base and Baltimore headquarters, Mira is well‑placed to leverage regulatory pathways and commercial distribution networks. The forthcoming IND submission is a critical milestone that will determine the pace of clinical development and, ultimately, market entry.

This article provides a forward‑looking analysis based on current market data and recent corporate disclosures. All figures are as reported and subject to change with subsequent market movements or regulatory developments.